86 results
10-Q
2024 Q1
BOLD
Boundless Bio Inc.
13 May 24
Quarterly report
7:06am
Number | Weighted- Average Exercise Price | Weighted- Average Remaining Term | Aggregate- Intrinsic Value (in 000’s) | |||||||||||
Balance as of December 31, 2023 | 2,813,937 | $ | 4.10 | 7.8 years | $ | 562 | ||||||||
Granted | 1,375,088 | $ | 11.23 | |||||||||||
Exercised | (15,104) | $ | 3.90 | |||||||||||
Forfeited and expired | (4,040) | $ | 4.05 | |||||||||||
Balance as of March 31, 2024 | 4,169,881 | $ | 6.47 | 8.9 years | $ | 33,378 | ||||||||
Vested and expected to vest at March 31, 2024 | 1,096,002 | $ | 4.13 | 7.6 years | $ | 11,086 | ||||||||
Exercisable as of March 31, 2024 | 1,161,181 | $ | 4.20 | 7.7 years | $ | 11,666 |
10-Q
2024 Q1
BOLD
Boundless Bio Inc.
13 May 24
Quarterly report
7:06am
Three Months Ended March 31, | ||||||||
2024 | 2023 | |||||||
Operating expenses: | ||||||||
Research and development | $ | 13,129 | $ | 9,503 | ||||
General and administrative | 3,754 | 2,584 | ||||||
Total operating expenses | 16,883 | 12,087 | ||||||
Loss from operations | (16,883) | (12,087) | ||||||
Other income (expense): | ||||||||
Interest income | 1,421 | 395 | ||||||
Other income (expense) | 32 | (27) | ||||||
Total other income, net | 1,453 | 368 | ||||||
Net loss | $ | (15,430) | $ | (11,719) | ||||
Net loss per share, basic and diluted | $ | (12.27) | $ | (9.91) | ||||
Shares used in calculation | 1,258 | 1,183 | ||||||
Comprehensive loss: | ||||||||
Net loss | $ | (15,430) | $ | (11,719) | ||||
Unrealized gain/(loss) on short-term investments | (61) | 278 | ||||||
Comprehensive loss | $ | (15,491) | $ | (11,441) |
10-Q
2024 Q1
BOLD
Boundless Bio Inc.
13 May 24
Quarterly report
7:06am
Convertible Preferred Stock | Common Stock | Accumulated other | Total | ||||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Additional paid-in-capital | comprehensive income/ (loss) | Accumulated deficit | stockholders’ deficit | ||||||||||||||||||||||||||
Balance at December 31, 2023 | 287,446,844 | $ | 247,617 | 1,247,012 | $ | - | $ | 8,987 | $ | 40 | $ | (136,109) | $ | (127,082) | |||||||||||||||||||
Vesting of early exercised stock options | — | — | 522 | — | 2 | — | — | 2 | |||||||||||||||||||||||||
Exercise of stock options | — | — | 15,104 | — | 59 | — | — | 59 | |||||||||||||||||||||||||
Stock-based compensation | — | — | — | — | 1,328 | — | — | 1,328 | |||||||||||||||||||||||||
Unrealized loss on short-term investments | — | — | — | — | — | (61) | — | (61) | |||||||||||||||||||||||||
Net loss | — | — | — | — | — | — | (15,430) | (15,430) | |||||||||||||||||||||||||
Balance at March 31, 2024 | 287,446,844 | $ | 247,617 | 1,262,638 | $ | - | $ | 10,376 | $ | (21) | $ | (151,539) | $ | (141,184) | |||||||||||||||||||
Balance at December 31, 2022 | 144,589,706 | $ | 147,946 | 1,167,240 | $ | - | $ | 5,377 | $ | (398) | $ | (86,675) | (81,696) | ||||||||||||||||||||
Vesting of early exercised stock options | — | — | 17,505 | — | 52 | — | — | 52 | |||||||||||||||||||||||||
Exercise of stock options | — | — | 9,195 | — | 31 | — | — | 31 | |||||||||||||||||||||||||
Stock-based compensation | — | — | — | — | 615 | — | — | 615 | |||||||||||||||||||||||||
Unrealized gain on short-term investments | — | — | — | — | — | 278 | — | 278 | |||||||||||||||||||||||||
Net loss | — | — | — | — | — | — | (11,719) | (11,719) | |||||||||||||||||||||||||
Balance at March 31, 2023 | 144,589,706 | $ | 147,946 | 1,193,940 | $ | - | $ | 6,075 | $ | (120) | $ | (98,394) | $ | (92,439) |
10-Q
2024 Q1
BOLD
Boundless Bio Inc.
13 May 24
Quarterly report
7:06am
Three Months Ended March 31, | ||||||||
2024 | 2023 | |||||||
Cash flows from operating activities | ||||||||
Net loss | $ | (15,430) | $ | (11,719) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Stock-based compensation | 1,328 | 615 | ||||||
Depreciation | 263 | 237 | ||||||
Accretion of investments, net | (972) | (117) | ||||||
Non-cash lease expense | 618 | 533 | ||||||
Other | — | 25 | ||||||
Changes in operating assets and liabilities: | ||||||||
Prepaid expenses and other assets | (701) | (225) | ||||||
Accounts payable and accrued liabilities | (210) | (904) | ||||||
Operating lease liabilities | (672) | (535) | ||||||
Net cash used in operating activities | (15,776) | (12,090) | ||||||
Cash flows from investing activities | ||||||||
Purchases of investments | (21,025) | (9,994) | ||||||
Maturities of investments | 39,245 | 32,246 | ||||||
Purchases of property and equipment | (83) | (86) | ||||||
Net cash provided by investing activities | 18,137 | 22,166 | ||||||
Cash flows from financing activities | ||||||||
Proceeds from the exercise of stock options | 59 | 31 | ||||||
Payment of deferred offering costs | (983) | — | ||||||
Net cash provided by / (used in) financing activities | (924) | 31 | ||||||
Net increase in cash and cash equivalents | 1,437 | 10,107 | ||||||
Cash, cash equivalents, and restricted cash at beginning of period | 24,266 | 11,484 | ||||||
Cash, cash equivalents, and restricted cash at end of period | $ | 25,703 | $ | 21,591 | ||||
Components of cash, cash equivalents, and restricted cash | ||||||||
Cash and cash equivalents | $ | 25,143 | $ | 21,058 | ||||
Restricted cash | 560 | 533 | ||||||
Cash, cash equivalents, and restricted cash at end of year | $ | 25,703 | $ | 21,591 | ||||
Non-cash investing and financing activities | ||||||||
Deferred offering costs in accounts payable and accrued liabilities | $ | 2,144 | $ | — | ||||
Addition to ROU assets | $ | — | $ | 282 | ||||
Increase to ROU assets due to remeasurement of lease obligation | $ | — | $ | 646 | ||||
Vesting of early exercised stock options | $ | 2 | $ | 52 | ||||
Unpaid property and equipment purchases | $ | 24 | $ | 26 |
10-Q
2024 Q1
BOLD
Boundless Bio Inc.
13 May 24
Quarterly report
7:06am
Pro Forma | ||||||||
(in thousands) | March 31, 2024 | March 31, 2024 | ||||||
Cash, cash equivalents, and short-term investments | $ | 104,880 | $ | 197,880 | ||||
Deferred offering costs | $ | 5,281 | $ | - | ||||
Convertible preferred stock | $ | 247,617 | $ | - | ||||
Common stock | $ | - | $ | 2 | ||||
Additional paid-in capital | $ | 10,376 | $ | 345,710 | ||||
Total stockholders' (deficit) equity | $ | (141,184) | $ | 194,153 |
10-Q
fhys8zh
13 May 24
Quarterly report
7:06am
10-Q
5j7074vpkjyhnm1rqj09
13 May 24
Quarterly report
7:06am
10-Q
238r5nhy63vze a7ah0q
13 May 24
Quarterly report
7:06am
10-Q
l6w80gkrw5z cjzkfc3
13 May 24
Quarterly report
7:06am
10-Q
wulyz7 gmf05zoqa7nbo
13 May 24
Quarterly report
7:06am
10-Q
yt4ll6
13 May 24
Quarterly report
7:06am
10-Q
bmtljdsklswuqyqymohj
13 May 24
Quarterly report
7:06am
10-Q
chzrj id2rq
13 May 24
Quarterly report
7:06am
10-Q
uhf8 qagal
13 May 24
Quarterly report
7:06am
10-Q
1fho4ps3viocscgkv yb
13 May 24
Quarterly report
7:06am
10-Q
fqsrv89 23ntmky
13 May 24
Quarterly report
7:06am
10-Q
nzd45ugctq
13 May 24
Quarterly report
7:06am
10-Q
thh7zbxx63 hd
13 May 24
Quarterly report
7:06am
10-Q
7ju kcdp1s
13 May 24
Quarterly report
7:06am
10-Q
jbt 4tryjp4m8
13 May 24
Quarterly report
7:06am